P195  Efficacy of ixekizumab versus adalimumab in psoriatic arthritis (PsA) patients with and without moderate-to-severe psoriasis: 52-week results from a multicentre, randomised open-label study

Conclusion In pts with active PsA, a significantly higher proportion of IXE-treated pts achieved the combined ACR50+PASI100 endpoint, and PASI100 at wk 52 vs. ADA, regardless of baseline PsO severity. ACR50 response at wk 24 and 52 was not influenced by IXE dosing. Faster improvements in MDA and DAPSA remis sion were observed with IXE than with ADA. These results were consistent with the overall SPIRIT-H2H population.Disclosure L. Kristensen: Consultancies; LE. Kristensen is a consultant for Amgen, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Forward Pharma, Janssen, Merck and Co., Novartis, Pfizer, UCB.M. Okada: Consultancies; M. Okada is a consultant for Eli Lilly and Company. Member of speakers ’ bureau; M. Okada is on the speaker’s bureau of: Santen Pharmaceutical, Mitsubishi Tanabe Pharma, Pfizer, Abbott Japan.W. Tillett: Honoraria; W. Tillett has received grants/speaker fees and/or honoraria from Abbvie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.S. Liu Leage: Shareholder/stock ownership; S.L. League is a shareholder and employee of Eli Lilly and Company.C. El Baou: Shareholder/stock ownership; C. El Baou is a shareholder and employee of Eli Lilly and Company.A.J. Bradley: Shareholder/stock ownership; A. Bradley is a shareholder and employee of Eli Lilly and Company.G. Meszaros: Shareholder/stock ownership; G. Meszaros is a shareholder and employee of Eli Lilly and Company.K. de Vlam: Consultancies; K. de Vlam is a consultant for Cel...
Source: Rheumatology - Category: Rheumatology Source Type: research